Marker Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 8
- Market Cap
- -
- Introduction
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
Lymphodepletion Enhances MAR-T Cell Therapy Efficacy in Lymphoma Patients, Marker Therapeutics Reports
• Marker Therapeutics' Phase 1 APOLLO study shows lymphodepletion significantly improves expansion and persistence of MT-601 MAR-T cells in lymphoma patients, potentially enhancing anti-tumor activity.
• Early clinical data reveals promising efficacy with 78% objective response rate and 44.4% complete response rate in patients who relapsed after or are not candidates for anti-CD19 CAR-T therapy.
• The non-genetically modified MAR-T cell approach targets six different tumor antigens, demonstrating excellent safety with no dose-limiting toxicities while potentially offering manufacturing advantages over current engineered T cell therapies.
FibroBiologics Opens New Houston Laboratory to Accelerate Fibroblast-Based Therapeutics Development
• FibroBiologics has unveiled a new 10,000-square-foot laboratory facility in Houston that will bring manufacturing operations in-house and accelerate development of fibroblast-based therapeutics for chronic diseases.
• The expanded facility will increase the company's research capabilities, reduce reliance on external partners like Charles River Laboratories, and enable FibroBiologics to streamline its supply chain for cell therapy products.
• With 240+ patents issued and pending, FibroBiologics plans to hire additional researchers to support its growing pipeline of candidates targeting multiple chronic disease indications using its proprietary fibroblast technology.
Marker Therapeutics' MT-601 Shows 78% Response Rate in Refractory Lymphoma Patients
• Marker Therapeutics' lead MAR-T cell therapy MT-601 (neldaleucel) demonstrated a 78% objective response rate in lymphoma patients who relapsed after anti-CD19 CAR-T therapy, with 44.4% achieving complete responses.
• The company secured over $13 million in non-dilutive funding from CPRIT and NIH to support clinical programs for pancreatic cancer and lymphoma, while also raising $16.1 million through a private placement.
• MT-601 showed a favorable safety profile with no immune-effector cell associated neurotoxicity syndrome and only one case of Grade 1 cytokine release syndrome reported in the Phase 1 APOLLO trial.
Marker Therapeutics Reports Positive Clinical Outcomes for MT-601 in Lymphoma Patients
Marker Therapeutics has provided a clinical update on its Phase 1 APOLLO study of MT-601, showing positive outcomes in patients with lymphoma who have relapsed after CD19 CAR-T cell therapy. The study highlights the potential of MT-601 to address a significant unmet medical need, with observed objective responses in heavily pre-treated patients.
Eisbach Bio Relocates to Houston with $4.75M CPRIT Grant to Advance EIS-12656 Trial in HRD Tumors
• Eisbach Bio is relocating to Houston, supported by a $4.75 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
• The funding will support Phase 2 clinical trials of EIS-12656, a therapy targeting homologous recombination deficiency (HRD) tumors.
• EIS-12656 functions by suppressing cancer-related genome reorganization caused by DNA damage, offering a novel approach to cancer treatment.
• CPRIT's investment aims to establish Texas as a hub for innovative cancer treatments and expand clinical options for HRD patients.
LIfT Biosciences Awarded ScaleReady G-Rex Grant to Advance N-LIfT Cell Therapy Manufacturing
• LIfT Biosciences receives a $300,000 G-Rex Grant from ScaleReady to bolster clinical manufacturing of its N-LIfT platform.
• The N-LIfT platform utilizes Immunomodulatory Alpha Neutrophils (IMANs) to target and kill solid tumors while activating the patient's immune system.
• The collaboration aims to establish a scalable, closed, and semi-automated G-Rex manufacturing process for late-stage clinical trials and beyond.
• LIfT Biosciences' N-LIfT therapy represents a novel approach to overcoming treatment resistance in solid tumors through its unique mechanism of action.
© Copyright 2025. All Rights Reserved by MedPath